Eli Lilly taps Entos' delivery tech in $50M-plus nucleic acid pact

Entos Pharmaceuticals’ star is rising. Just a few short months after the biotech’s nucleic acid delivery tech helped land a deal with BioMarin, the Edmonton, Alberta-based Canadian company has teamed up with Eli Lilly for $50 million upfront to drive its proteolipid vehicles (PLVs) toward a range of nervous system targets.